Extract
By the end of 2016, approximately 23 million Xpert MTB/RIF® (Xpert; Cepheid, Sunnyvale, CA, USA) cartridges for tuberculosis (TB) diagnosis had been procured by the public sector in 130 countries at concessional pricing [1], but smear microscopy continues to be the most widely used test for TB [2]. To understand the true market penetration of Xpert in TB high burden countries (HBCs), we surveyed National TB Programmes (NTPs) or their partnering organisations in 22 HBCs to obtain Xpert data from 2015 and to assess dynamic trends from 2014 to 2015. These 22 countries had been previously surveyed by us in 2014 [3].
Abstract
Uptake of Xpert in 22 high burden countries has progressed well since 2014, although more can be done to reach scale http://ow.ly/Whvu30dpqVI
Acknowledgements
We are grateful to survey respondents from 22 countries for their time and support.
Footnotes
Support statement: This study was supported by a FIND-McGill Partnership grant. Funding information for this article has been deposited with the Crossref Funder Registry.
Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com
- Received May 4, 2017.
- Accepted May 31, 2017.
- Copyright ©ERS 2017